Abstract

AbstractPre-eclampsia (PE) is a disease of high maternal, fetal, and neonatal mortality and morbidity. Early recognition, ideally in the first trimester of women at risk for PE will enable prophylaxis and help reduce associated adverse outcomes. No single test is supported by robust evidence to predict PE and no single test has emerged as a front runner. Screening based on risk factors has low sensitivity. Uterine artery Doppler is the primary screening modality for prediction of PE. Individually, no biomarker has shown to have sufficient clinical value in prediction of PE. However, sFlt-1/PlGF ratio performs better than others. A combination of uterine artery Doppler, maternal serum biomarkers, and maternal characteristics offers best predictive power at the moment.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call